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Background: The anticancer effects of selenium may be mediated by selenium-binding proteins, such as SELENBP1.
The association between SELENBP1 expression levels and clinicopathologic parameters was assessed in renal cell
carcinoma (RCC).
Methods: SELENBP1 mRNA expression was measured with real-time quantitative polymerase chain reaction (qPCR)
in 139 specimens of primary RCC and 59 specimens of donor-matched normal-appearing kidney tissues. The prognostic
effect of SELENBP1 levels was evaluated with Kaplan–Meier and multivariate Cox regression analyses.
Results: SELENBP1 mRNA levels were significantly lower in tumor tissues than in matched normal kidney tissues
(P < 0.001) and significantly inversely correlated with pathologic (T-stage and Fuhrman grade) and prognostic
variables (progression and cancer-specific death). Kaplan–Meier estimates showed that low SELENBP1 expression
was significantly correlated with cancer-specific death (log-rank test, P = 0.014), and a multivariate Cox regression
model revealed that SELENBP1 expression was an independent predictor of cancer-specific death (HR, 0.111; P = 0.006).
Conclusions: SELENBP1 might play a role in tumor suppression and could be a useful prognostic factor in RCC.
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Kidney cancer composes 5% and 3% of malignancies in
male and female patients, respectively, with approxi-
mately 63,920 new diagnoses in 2014 and 13,860 deaths
of the disease in the United States [1]. Renal cell carcin-
oma (RCC) is the most frequently occurring malignant
tumor of the kidney in adults [2]. Approximately one
third of RCC patients experience local or distant recur-
rence after definitive surgery [3]. Recognized prognostic
factors, such as pathologic staging and histologic grad-
ing, are not sufficient for prognosis when used alone [4].* Correspondence: wjkim@chungbuk.ac.kr
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unless otherwise stated.Therefore, it is crucial to identify biologic markers to
find patients at high risk for disease progression.
Selenium is a trace element that is essential for a num-
ber of biologic processes. Supplemental dietary selenium
was first observed to play a role in reducing cancer risk
more than 40 years ago [5]. A deficiency in dietary selen-
ium is associated with an increased incidence of epithe-
lial cancers, including lung, liver, colorectal, and prostate
cancer [6]. The antitumor function of selenium is thought
to be mediated through selenium-binding protein 1
(SELENBP1). The SELENBP1 gene is located on chromo-
some 1q21–22; the mRNA sequence of the gene is com-
posed of 1,721 nucleotides encoding 640 amino acids [7].
SELENBP1 mRNA is abundantly expressed in many types
of tissues [8]. Its expression is reduced markedly in mul-
tiple epithelial cancers compared with normal tissues, sug-
gesting a possible link to malignancies associated with
selenium deficiencies [9-13]. Moreover, reduced selenium-
binding protein 1 expression is associated with poorThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 PCR primer sequences
Human SELENBP1 forward GGGAGGTACATGGTCAGTGG
Human SELENBP1 reverse GGAAGAGCTGTCCTGTGAGG
Human GAPDH forward TGCACCACCAACTGCTTAGC
Human GAPDH reverse GGCATGGACTGTGGTCATGAG
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SELENBP1 may play a critical role in regulating malignant
transformation and cancer progression. Nevertheless, little
information is available on the expression and function
of SELENBP1 during the RCC carcinogenic process in
humans, and the significance of SELENBP1 expression
in RCC is still largely unknown.
The aims of the present study were (a) to compare the
expression level of SELENBP1 in the tumor with that in
normal adjacent tissue, and (b) to define the value of
SELENBP1 expression for predicting tumor outcomes,
such as progression and cancer-related death.
Methods
Study population and clinical specimens
Between April 1996 and December 2010, RCC samples
were obtained from 139 patients with primary RCC who
underwent radical nephrectomy or partial nephrectomy
at the Chungbuk National University Hospital. Donor-
matched normal-appearing kidney tissues (≥5 mm from
the tumor tissue) were obtained from 59 patients. The
study was in agreement with the Declaration of Helsinki
and received Institutional Review Board approval (IRB
approval number 2006-01-001). All participating patients
gave written informed consent. All tumors were macro-
dissected within 15 minutes of surgical resection, flash-
frozen in liquid nitrogen, and stored at −80°C until use.
Staging of RCC was performed as per the American
Joint Committee on Cancer (AJCC) staging manual [16].
Histologic differentiation was evaluated by using the
Fuhrman nuclear grading system [17]. All patients were
evaluated postoperatively every 3 months for the first
2 years, every 6 months for the following 2 years, and
yearly thereafter. The definition of disease progression
included local recurrence, lymph node metastasis, and
distant metastasis by CT scan and bone scan.
RNA extraction and construction of cDNA
Total RNA was separated from tissue homogenized in a
5-ml glass tube in 1 ml TRIzol (Invitrogen, Carlsbad,
CA, USA). The homogenate was transferred to a 1.5-ml
tube and mixed with 200 μl of chloroform. After incuba-
tion for 5 minutes at 4°C, the homogenate was centri-
fuged for 13 minutes at 13,000 g and 4°C. The upper
aqueous phase was transferred to a clean tube, 500 μl of
isopropanol was added, and the mixture was incubated
for 60 minutes at 4°C. The sample was then centrifuged
for 8 minutes at 13,000 g and 4°C. Then the upper aque-
ous phase was removed, mixed with 500 μl of 75% etha-
nol, and centrifuged for 5 minutes at 13,000 g and 4°C.
After the upper aqueous layer was discarded, the pellet
was dried at room temperature, dissolved with diethyl-
pyrocarbonate (DEPC)-treated water, and stored at −80°C.
The quality and integrity of the RNA were confirmed withagarose gel electrophoresis and ethidium bromide staining.
cDNA was then prepared from 1 μg of total RNA by using
the First-Strand cDNA Synthesis kit (Clontech, TAKARA,
Otsu, Japan) according to the manufacturer’s protocol.
Real-time quantitative polymerase chain reaction (qPCR)
To quantify mRNA expression levels, qPCR amplification
was performed by using a Rotor-Gene 6000 instrument
(Corbett Research, Mortlake, Australia). qPCR assays were
carried out in microreaction tubes (Corbett Research) by
using SYBR premix EX Taq (TAKARA BIO Inc., Otsu,
Japan) and SELENBP1 primers. The PCR reaction was
performed in a final volume of 10 μl, consisting of 5 μl of
2 × SYBR premix EX Taq buffer, 0.5 μl of each primer (10
pM/μl), and 2 μl of cDNA. The product was purified with
a QIAquick Extraction kit (QIAGEN, Hilden, Germany),
quantified with a spectrometer (Perkin Elmer MBA-2000,
Fremont, CA, USA), and sequenced with an automated
laser fluorescence sequencer (ABI PRISM 3100 Genetic
Analyzer, Foster City, CA, USA). The product was serially
diluted from 100 pg/μl to 0.1 pg/μl to establish a standard
curve. The qPCR conditions were 1 cycle at 96°C for
20 seconds, followed by 40 cycles of 3 seconds at 96°C
for denaturation, 15 seconds at 60°C for annealing,
and 15 seconds at 72°C for extension. The melting pro-
gram was performed at 72°C to 95°C with a heating
rate of 1°C per 45 seconds. Spectral data were captured
and analyzed by using the Rotor-Gene Real-Time Ana-
lysis Software 6.0 Build 14 (Corbett Research). All
samples were run in triplicate. Glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) was used as a reference
gene. SELENBP1 expression was normalized to that of
GAPDH. Primer sequences are shown in Table 1.
Statistics
To normalize the highly skewed distribution of SELENBP1
mRNA expression, the data were examined as natural log
and subsequently back-transformed to express the model
results as geometric mean (antilog 95% confidence interval
(CI) [18]. To compare gene-expression levels among the
groups, a two-sample t test or ANOVA was performed.
Spearman correlation coefficients were performed to
evaluate the association between the SELENBP1 expres-
sion and clinicopathologic parameters. Patients were clas-
sified as having high or low expression of SELENBP1, with
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value. The Kaplan–Meier method was used to estimate
the time to progression and cancer-specific death, and dif-
ferences were assessed by using log-rank statistics. The
prognostic value of SELENBP1 expression was analyzed
by using a multivariate Cox proportional hazards regres-
sion model. Statistical analysis was performed by using
IBM SPSS ver. 20.0 (IBM Co., Armonk, NY, USA), and
P < 0.05 was considered statistically significant.Results
SELENBP1 mRNA expression in RCC and surrounding
donor-matched normal tissues
Paired tissue samples (tumor tissue and donor-matched
adjacent normal tissue) were collected from 59 patients
with RCC. As shown in Figure 1, the mRNA level of
SELENBP1 in RCC tissues was apparently lower than in
normal adjacent kidney tissues (P < 0.001).Baseline characteristics in RCC patients
Table 2 lists the baseline characteristics of the 139 RCC
patients recruited in this study. The median age of the
RCC patients was 58 years (range, 21 to 83 years). At the
time of diagnosis, 114 (82%) patients had local disease
(pT1/pT2), and 25 (18%) had locally advanced disease
(pT3/pT4). The Fuhrman nuclear grades were 1, 2, 3, and
4 in 25 (18.0%), 58 (41.7%), 43 (30.7%), and 13 (9.4%)
cases, respectively. Ten (7.2%) N+ and nine (6.5%) M+ pa-
tients were in our study population. The median follow-
up period was 42.9 months (range, 1.0 to 156.8 months).Figure 1 Selenium-binding protein 1 (SELENBP1) mRNA levels in tum
cell carcinoma (RCC) assessed with qPCR.Relation between SELENBP1 mRNA expression levels and
clinicopathologic features
The expression of SELENBP1 mRNA was significantly
lower in cancer specimens from patients with high-
grade, locally advanced T stage (pT3/pT4), progression,
and cancer-specific death than in those with low-grade,
local disease (pT1/pT2) and nonprogression who sur-
vived or died of other causes than RCC (P = 0.042, P =
0.034, P = 0.009, and P = 0.002, respectively) (Table 3).
On correlation analysis, the SELENBP1 expression cor-
related significantly with pathologic stage (r = −0.200;
P = 0.018). However, no significant correlation was found
between Fuhrman grade and SELENBP1 expression
(r = −0.072; P =0.399). When we examined the tumor
diameters, the median tumor size was 4.5 cm (range,
1–17 cm). SELENBP1 mRNA levels showed signifi-
cant correlation with tumor dimensions (r = −0.184;
P = 0.030).
Prognostic value of SELENBP1 mRNA expression levels for
progression and cancer-specific death in RCC
Kaplan–Meier analysis revealed prolonged cancer-specific
survival in high-SELENBP1 expressors compared with low
expressors in RCC (P = 0.014) (Figure 2B). Progression-
free survival had marginal association with SELENBP1
(P = 0.059) (Figure 2A). Univariate analysis using a Cox
proportional hazards model to evaluate the potential
utility of SELENBP1 mRNA expression as a prognostic
marker in RCC after surgery showed that SELENBP1
expression (P = 0.019), Fuhrman grade (P = 0.010), N stage
(P < 0.001), M stage (P < 0.001), and T stage (P < 0.001)or tissues and adjacent normal tissues in 59 patients with renal
Table 2 Baseline characteristics
Variables Incidence (%) or value
Median age (range) 58 years (21–83)
















N0 or Nx 129 (92.8)
N+ 10 (7.2)
M stage







Table 3 mRNA expression of SELENBP1 versus
clinicopathologic parameters in RCC
Parameters (N) mRNA expression
level (×106 copies/μl)
P
Pathologic T-stage (Low versus
High stage)
0.034
pT1–2 (114) 0.64 (0.51–0.81)
pT3–4 (25) 0.36 (0.22–0.57)
T stage (individual stage) 0.030
pT1 (93) 0.64 (0.50–0.82)
pT2 (21) 0.55 (0.35–0.70)
pT3 (20) 0.40 (0.23–0.61)
pT4 (5) 0.23 (0.10–0.41)
N stage 0.267
N0 or Nx (129) 0.60 (0.48–0.74)
N+ (10) 0.38 (0.16–0.86)
M stage 0.855
M0 or Mx 0.58 (0.47–0.72)
M1 0.54 (0.24–1.21)
Nuclear grade
1 (25) 0.63 (0.43–0.94) 0.042
2 (58) 0.59 (0.42–0.83)
3 (43) 0.70 (0.48–1.03)
4 (13) 0.23 (0.11–0.49)
Progression 0.009
No (115) 0.65 (0.52–0.82)
Yes (24) 0.31 (0.19–0.52)
Cancer-specific death 0.002
No (122) 0.65 (0.52–0.81)
Yes (17) 0.24 (0.13–0.421)
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After adjusting for clinicopathologic variables, SELENBP1
expression (P = 0.006), N stage (P < 0.001), and T stage
(P = 0.033) remained significantly correlated with cancer-
related death in RCC (Table 4).
Discussion
Biologic markers may enhance our understanding of the
pathogenesis of RCC and have value in prognosis and
treatment. Lucas et al. [19] showed that the downregula-
tion of hepatocyte nuclear factor 4 alpha (HNF4α) in
RCC could be interpreted as an indication that (HNF4α)
plays a role as a tumor suppressor. Bui et al. [20] re-
ported that Ki67 and carbonic anhydrase IX (CA9) were
significant predictors of survival and histologic grade.
Hypoxia-induced factor-1 alpha (HIF-1a) was found to
be an independent prognostic factor for patients with
metastatic clear cell RCC [21]. Jacobsen et al. [22] found
that serum vascular endothelial growth factor (VEGF)level was significantly correlated to tumor stage and
grade. Serum C-reactive protein (CRP) was also a robust
predictor of metastasis and mortality after curative
nephrectomy [23,24]. From the report from Lucarelli
et al. [25], a famous tumor marker CA 15–3 was an in-
dependent adverse predictor for cancer-specific sur-
vival in RCC patients [25]. Despite intensive effort, no
biologic markers are available for routine use in the
clinic.
SELENBP1, a member of the selenoprotein family,
binds selenium covalently and mediates the intracellular
transport of selenium [26-28]. Epidemiologic and clinical
trial data demonstrate that a deficiency in dietary selen-
ium is associated with an increased incidence of epithe-
lial cancers [6,29]. Nutritional levels of selenoproteins
are enough to mediate the anticancer properties of sel-
enium. Little information is available on the expression
and function of SELENBP1 during the RCC carcinogenic
process in humans. The present results suggest for the
Figure 2 Effect of SELENBP1 expression on progression-free survival (A) and cancer-specific survival (B).
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volved in human RCC tumorigenesis and be an inde-
pendent predictor of cancer-specific death in RCC.
SELENBP1 is downregulated in several tumor types. In
a study of breast cancer samples, the level of SELENBP1
was decreased in tumor tissues compared with normal
tissues and correlated with late disease stages and poor
survival [30]. In addition, Zeng et al. [31] detected pro-
gressive reduction of SELENBP1 during the human bron-
chial epithelial carcinogenic process and found that the
expression levels of SELENBP1 could distinguish normal
bronchial epithelium from preneoplastic lesions and inva-
sive lung squamous cell cancer. Similarly, reduced levels
of SELENBP1 are an indicator of poor prognosis in colon
cancer [10,14]. In prostate cancer, low levels of SELENBP1
were suggestively associated with increased Gleason Score
and poor clinical outcome [32]. Zhang et al. [33] demon-
strated a significant decrease in SELENBP1 in uterine leio-
myoma compared with normal myometrium, suggestingTable 4 Univariate and multivariate Cox regression analysis f
Variables Univariate
HR (95% CI)
Age (<58 versus≥ 58) 1.372 (0.510–3.692)
Sex (male versus female) 0.984 (0.343–2.822)
T stage (T1–2 versus T3–4) 9.378 (3.424–25.689)
N Stage (N0 or Nx versus N+) 15.602 (5.304–45.892)
M Stage (M0 or Mx versus M1) 8.264 (2.826–24.166)
Fuhrman grade (1–2 versus 3–4) 3.996 (1.402–11.392)
SELENBP expression (low versus high) 0.168 (0.038–0.741)that SELENBP1 may be performing its normal biologic
function in healthy myometrium. Similar results were ob-
tained in gastric cancer, in which SELENBP1 was detected
in all cases of nonneoplastic epithelial tissues but was ab-
sent in gastric cancer [34]. These findings indicate that
suppression of SELENBP1 might be a late molecular event
in gastric carcinoma. The pattern of SELENBP1 staining
may provide useful information about the molecular
changes that occur during gastric carcinogenesis. Our re-
sults in RCC are consistent with these previous findings.
Our study is not without weaknesses. First, the num-
bers of enrolled samples were relatively small, and the
study design was retrospective. Second, the exact mech-
anisms by which SELENBP1 contributes to tumorigenesis
in RCC are not known. In vitro and in vivo laboratory re-
search is needed to elucidate these mechanisms. Third, we
did not evaluate the protein level of SELENBP1, such as
by Western blot or immunohistochemical (IHC) staining.
In particular, IHC staining of SELENBP1 in RCC tissues isor prediction of cancer-related death in RCC
Multivariate
P HR (95% CI) P
0.531 1.249 (0.427–3.651) 0.685
0.976 0.953 (0.260–4.615) 0.532
<0.001 4.432 (1.127–17.425) 0.033
<0.001 20.373 (4.439–93.498) <0.001
<0.001 1.761 (0.529–5.859) 0.356
0.010 3.015 (0.697–13.033) 0.140
0.019 0.111 (0.023–0.529) 0.006
Ha et al. World Journal of Surgical Oncology 2014, 12:288 Page 6 of 7
http://www.wjso.com/content/12/1/288planned. Prospective studies in larger patient populations
with longer follow-up periods will improve our under-
standing of the value of SELENBP1 in RCC prognosis.
Conclusions
In conclusion, our study found that reduced SELENBP1
mRNA expression might play an important role in RCC
tumorigenesis: low SELENBP1 mRNA expression corre-
lates with aggressive disease and predicts cancer-specific
survival in RCC.
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